������

Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup. Pharmacogenomics allows us to identify sources of an individual’s profile of drug response and predict the best possible treatment option for this individual. The use of genomic information has opened new possibilities in drug discovery and development. Pharmacoproteomics is the use of proteomic technologies in drug discovery and development. Along with pharmacogenomics and pharmacogenetics, pharmacoproteomics will play an important role in the development of personalized medicines in several ways. Proteomic technologies are contributing to molecular diagnostics, which is a basis of personalized medicine. Pharmacoproteomics is a more functional representation of patient-to-patient variation than that provided by genotyping.

Related Journals: Annual Review of Genomics and Human Genetics, Applied and Translational Genomics, BMC Genomics, BMC Medical Genomics, Cancer Genomics and Proteomics, Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics, Current Chemical Genomics, Current Genomics, Current Pharmacogenomics and Personalized Medicine

Pharmacogenomics and Pharmacoproteomics

Conference Proceedings